Although no clinical trials have been initiated so far, IL-2/IL-2mAb complexes have high potential as a clinically feasible strategy; however, IL-2/IL-2mAb complex single treatment in the hemophilia A “inhibitor” mice only transiently reduced neutralizing antibody titers during treatment. This evidence concerns the gene IL2 and hemophilia A.